Insulin glargine HOE901
Sponsors
Sanofi
Conditions
Type 1 Diabetes MellitusType 2 Diabetes Mellitus
Phase 1
Study of How Single Rising Doses of SAR161271 Are Absorbed and Act in Patients With Type 1 Diabetes Mellitus (T1DM)
CompletedNCT01053728
Start: 2010-02-28End: 2010-11-30Updated: 2011-07-26
Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1
CompletedNCT01146678
Start: 2010-06-30End: 2011-01-31Target: 22Updated: 2011-03-02
Repeated Dosing Study With a New Insulin Glargine Formulation and Lantus® in Patients With Type 1 Diabetes Mellitus
CompletedNCT01349855
Start: 2011-03-31End: 2011-05-31Target: 30Updated: 2011-06-01
Single Dose Study With a New Insulin Glargine Formulation and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus
CompletedNCT01493115
Start: 2011-11-30End: 2012-04-30Updated: 2012-05-01
Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus
CompletedNCT02713477
Start: 2016-04-30End: 2016-06-30Updated: 2020-06-16
Phase 3
Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine
CompletedNCT02273180
Start: 2014-10-31End: 2016-07-31Updated: 2018-01-18
Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine
CompletedNCT02294474
Start: 2015-01-31End: 2016-02-29Updated: 2018-01-18